Literature DB >> 22706539

The role of the fallopian tube in ovarian cancer.

Alicia A Tone1, Shannon Salvador, Sarah J Finlayson, Anna V Tinker, Janice S Kwon, Cheng-Han Lee, Trevor Cohen, Tom Ehlen, Marette Lee, Mark S Carey, Mark Heywood, Judith Pike, Paul J Hoskins, Gavin C Stuart, Kenneth D Swenerton, David G Huntsman, C Blake Gilks, Dianne M Miller, Jessica N McAlpine.   

Abstract

High-grade serous carcinoma (HGSC) is the most common and lethal subtype of ovarian cancer. Research over the past decade has strongly suggested that "ovarian" HGSC arises in the epithelium of the distal fallopian tube, with serous tubal intraepithelial carcinomas (STICs) being detected in 5-10% of BRCA1/2 mutation carriers undergoing risk-reducing surgery and up to 60% of unselected women with pelvic HGSC. The natural history, clinical significance, and prevalence of STICs in the general population (ie, women without cancer and not at an increased genetic risk) are incompletely understood, but anecdotal evidence suggests that these lesions have the ability to shed cells with metastatic potential into the peritoneal cavity very early on. Removal of the fallopian tube (salpingectomy) in both the average and high-risk populations could therefore prevent HGSC, by eliminating the site of initiation and interrupting spread of potentially cancerous cells to the ovarian/peritoneal surfaces. Salpingectomy may also reduce the incidence of the 2 next most common subtypes, endometrioid and clear cell carcinoma, by blocking the passageway linking the lower genital tract to the peritoneal cavity that enables ascension of endometrium and factors that induce local inflammation. The implementation of salpingectomy therefore promises to significantly impact ovarian cancer incidence and outcomes.

Entities:  

Mesh:

Year:  2012        PMID: 22706539

Source DB:  PubMed          Journal:  Clin Adv Hematol Oncol        ISSN: 1543-0790


  24 in total

1.  Short-term effects of salpingectomy during laparoscopic hysterectomy on ovarian reserve: a pilot randomized controlled trial.

Authors:  Austin D Findley; Matthew T Siedhoff; Kumari A Hobbs; John F Steege; Erin T Carey; Christina A McCall; Anne Z Steiner
Journal:  Fertil Steril       Date:  2013-08-29       Impact factor: 7.329

Review 2.  The Two Faces of Adjuvant Glucocorticoid Treatment in Ovarian Cancer.

Authors:  Vladimir Djedovic; Yoo-Young Lee; Alexandra Kollara; Taymaa May; Theodore J Brown
Journal:  Horm Cancer       Date:  2018-01-08       Impact factor: 3.869

3.  Examining the use of salpingectomy with hysterectomy in Canada.

Authors:  C Sandoval; M Fung-Kee-Fung; B Gilks; K J Murphy; R Rahal; H Bryant
Journal:  Curr Oncol       Date:  2013-06       Impact factor: 3.677

4.  The ovary is an alternative site of origin for high-grade serous ovarian cancer in mice.

Authors:  Jaeyeon Kim; Donna M Coffey; Lang Ma; Martin M Matzuk
Journal:  Endocrinology       Date:  2015-03-27       Impact factor: 4.736

Review 5.  Epidemiology of Patients with Ovarian Cancer with and Without a BRCA1/2 Mutation.

Authors:  Elisabete Weiderpass; Jerzy E Tyczynski
Journal:  Mol Diagn Ther       Date:  2015-12       Impact factor: 4.074

Review 6.  The disparate origins of ovarian cancers: pathogenesis and prevention strategies.

Authors:  Anthony N Karnezis; Kathleen R Cho; C Blake Gilks; Celeste Leigh Pearce; David G Huntsman
Journal:  Nat Rev Cancer       Date:  2016-11-25       Impact factor: 60.716

7.  Use of CA125 and HE4 serum markers to predict ovarian cancer in elevated-risk women.

Authors:  Beth Y Karlan; Jason Thorpe; Kate Watabayashi; Charles W Drescher; Melanie Palomares; Mary B Daly; Pam Paley; Paula Hillard; M Robyn Andersen; Garnet Anderson; Ronny Drapkin; Nicole Urban
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-05-01       Impact factor: 4.254

8.  Epigenetic remodeling regulates transcriptional changes between ovarian cancer and benign precursors.

Authors:  Kevin M Elias; Megan M Emori; Thomas Westerling; Henry Long; Anna Budina-Kolomets; Fugen Li; Emily MacDuffie; Michelle R Davis; Alexander Holman; Brian Lawney; Matthew L Freedman; John Quackenbush; Myles Brown; Ronny Drapkin
Journal:  JCI Insight       Date:  2016-08-18

Review 9.  Challenging and complex decisions in the management of the BRCA mutation carrier.

Authors:  Daniela L Stan; Lynne T Shuster; Myra J Wick; Casey L Swanson; Sandhya Pruthi; Jamie N Bakkum-Gamez
Journal:  J Womens Health (Larchmt)       Date:  2013-08-29       Impact factor: 2.681

10.  Proteomic analysis of temporally stimulated ovarian cancer cells for biomarker discovery.

Authors:  Mark A Marzinke; Caitlin H Choi; Li Chen; Ie-Ming Shih; Daniel W Chan; Hui Zhang
Journal:  Mol Cell Proteomics       Date:  2012-11-19       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.